[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Study’s contact

Call center

31-43-356-8328

Email address

VanDycKN@bsci.com

Condition

Parkinson's Disease

Treatment type

Observational [Patient Registry]

Investigational product

Deep Brain Stimulation (DBS)

Sponsor

Boston Scientific Corporation

ClinicalTrials.gov identifier

NCT02071134

Study number

A4010

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS system in the treatment of Parkinson's disease. Additionally, the utilization of Guide XT (GXT) System when used as a planning tool for the programming of patients with the Boston Scientific's Vercise DBS Systems is also evaluated.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria
  1. Meets criteria established in locally applicable Vercise System Direction for Use
  2. At least 18 years old Key
Exclusion criteria
  1. Meets any contraindication in the Vercise System locally applicable Directions for Use Subjects with significant cognitive or psychiatric impairment may be excluded in the evaluation of GXT.

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site